Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Refractory Malignant Ascites Clinical Trial

Official title:
Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.

Status Recruiting

Clinical Trial Summary

Malignant ascites often has a profound impact on the quality of life of cancer patients. Current treatments,including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab for the palliation of malignant ascites might be a novel choice for refractory malignant ascites.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01852409
Study type	Interventional
Source	Peking University
Contact	Lin Shen, M.D.
Phone	861088196561
Email	lin100@medmail.com.cn
Status	Recruiting
Phase	Phase 1
Start date	May 2013
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04771676` - Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites	Phase 2
Withdrawn	`NCT02477657` - Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology
Completed	`NCT02891369` - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
Recruiting	`NCT05303844` - Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites	Phase 1